# Cemiplimab Plus Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma

Source: https://onco.cc/trials/nct06790602/  
OnCo record `nct06790602` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial in pancreatic cancer, run by University of California, San Diego, now recruiting.

## Summary

Cemiplimab Plus Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma is a phase 2, interventional study registered as NCT06790602 by University of California, San Diego, with a registry enrolment figure of 43 participants, started 2026-05-06 and due to reach its primary completion in 2028-07. Interventions recorded: Cemiplimab Plus Gemcitabine. Conditions listed: Pancreatic Ductal Adenocarcinoma (mPDAC). Primary outcome: Overall survival. Pancreatic eligibility wording from the registry: "Histologically or cytologically confirmed pancreatic ductal adenocarcinoma". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Also known as: SWITCH
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT06790602
- Phase: 2
- Setting: A Single-arm, Open-label, Phase II Trial of Cemiplimab Plus Gemcitabine as Second-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma Harboring SWItch/Sucrose Non-Fermentable (SWI/SNF) Alterations.
- Sponsor: University of California, San Diego
- Enrolled: 43

## Sources

- ClinicalTrials.gov NCT06790602: https://clinicaltrials.gov/study/NCT06790602

## Connected records

- cancers: [Metastatic pancreatic ductal adenocarcinoma](https://onco.cc/cancers/metastatic-pdac/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06790602.json